FDA-Approved Radiopharmaceuticals

Radiopharmaceuticals have been steadily gaining recognition in medical imaging and targeted therapies. These pharmaceutical agents contain radioactive isotopes that emit radiation, which specialised imaging devices can detect. The FDA has approved several radiopharmaceuticals for various applications, including diagnosis, treatment evaluation, and therapy. One of the most well-known FDA-approved radiopharmaceuticals is Technetium-99m, used since the 1960s. This versatile agent can be incorporated into various compounds to target specific organs or physiological systems. Technetium-99m is primarily employed in single-photon emission computed tomography (SPECT) imaging to assess the function of organs such as the heart, lungs, and brain and to detect cancer metastases. Another important radiopharmaceutical is Fluorine-18 fluorodeoxyglucose (FDG), a positron emission tomography (PET) imaging standard. FDG accumulates in cells with high glucose metabolism, making it particularly useful for identifying tumours, as cancer cells are known for their increased metabolic activity. This agent has revolutionised cancer diagnosis, staging, and treatment response evaluation. Gallium-68 Dotatate is another FDA-approved radiopharmaceutical used in PET imaging. It specifically binds to somatostatin receptors, which are overexpressed in neuroendocrine tumours. This selective binding allows for accurate tumour localisation, disease staging, and monitoring of treatment response in patients with neuroendocrine tumours. In addition to diagnostic applications, radiopharmaceuticals have also shown potential in targeted therapies. Lutetium-177 Dotatate, for instance, is an FDA-approved peptide receptor radionuclide therapy (PRRT) that targets somatostatin receptor-positive neuroendocrine tumours. This therapeutic radiopharmaceutical minimises damage to healthy tissue and has demonstrated improved progression-free survival in clinical trials by delivering targeted radiation directly to the tumour site. Another example of a therapeutic radiopharmaceutical is Radium-223 dichloride, which is approved for treating metastatic castration-resistant prostate cancer with bone metastases. Radium-223 mimics calcium and selectively targets areas of bone metastases, delivering alpha radiation to cancer cells while sparing surrounding healthy tissue. Iodine-131 is a well-established therapeutic radiopharmaceutical used to treat hyperthyroidism and thyroid cancer. It accumulates in thyroid tissue, emitting beta radiation that destroys the overactive or cancerous cells, thus restoring normal thyroid function or eliminating malignant tissue. The FDA-approved radiopharmaceuticals mentioned above represent only a fraction of the growing field. Ongoing research and development of novel radiopharmaceuticals hold immense potential for improving the accuracy of disease diagnosis, monitoring treatment response, and providing targeted therapies for various conditions. As our understanding of molecular biology advances, so will the development of innovative radiopharmaceuticals that can revolutionise modern medicine.

Last Updated: 06Oct2024

You are here:
home » FDA-approved radiopharmaceuticals

FDA-approved radiopharmaceuticals revolutionise diagnostics and targeted therapies, enhancing accuracy and effectiveness in disease detection and treatment.
FDA-Approved Radiopharmaceuticals

Yttrium-90 Ibritumomab Tiuxetan (Zevalin): A Targeted Radioimmunotherapy Revolutionising the Treatment of Refractory B-Cell Non-Hodgkin’s Lymphoma

Zevalin, combining monoclonal antibodies and radiation, offers hope against refractory B-cell non-Hodgkin’s lymphoma with targeted therapy.

Yttrium-90 Ibritumomab Tiuxetan (Zevalin): A Targeted Radioimmunotherapy Revolutionising the Treatment of Refractory B-Cell Non-Hodgkin’s Lymphoma Read Post »

,
FDA-approved radiopharmaceuticals revolutionise diagnostics and targeted therapies, enhancing accuracy and effectiveness in disease detection and treatment.
FDA-Approved Radiopharmaceuticals

Technetium-99m Tilmanocept (Lymphoseek): Enhancing the Precision of Sentinel Lymph Node Biopsy in Oncologic Surgery

Lymphoseek offers targeted, efficient sentinel lymph node mapping, improving cancer staging and reducing surgical morbidity.

Technetium-99m Tilmanocept (Lymphoseek): Enhancing the Precision of Sentinel Lymph Node Biopsy in Oncologic Surgery Read Post »

, ,
FDA-approved radiopharmaceuticals revolutionise diagnostics and targeted therapies, enhancing accuracy and effectiveness in disease detection and treatment.
FDA-Approved Radiopharmaceuticals

Utilising Technetium-99m Labelled Red Blood Cells (UltraTag) in Blood Pool Imaging and the Detection of Gastrointestinal Bleeding

Technetium-99m UltraTag RBCs enhance blood pool imaging and precisely localize gastrointestinal bleeding in non-invasive diagnostic procedures.

Utilising Technetium-99m Labelled Red Blood Cells (UltraTag) in Blood Pool Imaging and the Detection of Gastrointestinal Bleeding Read Post »

,
FDA-approved radiopharmaceuticals revolutionise diagnostics and targeted therapies, enhancing accuracy and effectiveness in disease detection and treatment.
FDA-Approved Radiopharmaceuticals

Technetium-99m Exametazime (Ceretec): Overview of its Applications, Advantages, and Role in Medical Imaging

Technetium-99m exametazime (Ceretec) is a pivotal radiopharmaceutical in nuclear medicine, revolutionising brain imaging with high precision and reliability.

Technetium-99m Exametazime (Ceretec): Overview of its Applications, Advantages, and Role in Medical Imaging Read Post »

,
FDA-approved radiopharmaceuticals revolutionise diagnostics and targeted therapies, enhancing accuracy and effectiveness in disease detection and treatment.
FDA-Approved Radiopharmaceuticals

Radium-223 Dichloride (Xofigo): Targeted Alpha Therapy for Castration-Resistant Prostate Cancer with Bone Metastases

Radium-223 dichloride, a targeted alpha therapy, effectively treats castration-resistant prostate cancer with bone metastases, improving patients’ overall survival.

Radium-223 Dichloride (Xofigo): Targeted Alpha Therapy for Castration-Resistant Prostate Cancer with Bone Metastases Read Post »

,
FDA-approved radiopharmaceuticals revolutionise diagnostics and targeted therapies, enhancing accuracy and effectiveness in disease detection and treatment.
FDA-Approved Radiopharmaceuticals

Pluvicto (Lutetium-177 Vipivotide Tetraxetan): A Focused Assault on Metastatic Castration-Resistant Prostate Cancer

Lutetium-177 Vipivotide Tetraxetan – Pluvicto: Radiopharmaceutical for targeted cancer therapy. Innovative, promising, precise, advanced, therapeutic.

Pluvicto (Lutetium-177 Vipivotide Tetraxetan): A Focused Assault on Metastatic Castration-Resistant Prostate Cancer Read Post »

,
FDA-approved radiopharmaceuticals revolutionise diagnostics and targeted therapies, enhancing accuracy and effectiveness in disease detection and treatment.
FDA-Approved Radiopharmaceuticals

Iodine-131 Iobenguane (I-131 MIBG): A Radiopharmaceutical Powerhouse for Diagnosing and Treating Neuroendocrine Tumours

Iodine-131 Iobenguane (I-131 MIBG), a radiopharmaceutical agent, enables early diagnosis and targeted treatment of neuroendocrine tumours, improving patient outcomes.

Iodine-131 Iobenguane (I-131 MIBG): A Radiopharmaceutical Powerhouse for Diagnosing and Treating Neuroendocrine Tumours Read Post »

,
FDA-approved radiopharmaceuticals revolutionise diagnostics and targeted therapies, enhancing accuracy and effectiveness in disease detection and treatment.
FDA-Approved Radiopharmaceuticals

Copper-64 DOTATE: A Promising Radiopharmaceutical in Diagnostic Imaging and Targeted Therapy

Copper-64 DOTATE, a diagnostic radiopharmaceutical, effectively targets neuroendocrine tumours, enabling precise imaging and personalised treatment plans for cancer patients.

Copper-64 DOTATE: A Promising Radiopharmaceutical in Diagnostic Imaging and Targeted Therapy Read Post »

, , ,
Scroll to Top